@article{fdi:010086030,
  title = {{C}hronic kidney disease in a large national human immunodeficiency virus treatment program},
  author = {{P}aengsai, {N}. and {N}oppakun, {K}. and {J}ourdain, {G}onzague and {C}ressey, {T}. {R}. and {S}alvadori, {N}. and {C}haiwarith, {R}. and {T}antraworasin, {A}. and {M}ary, {J}. {Y}. and {B}owonwatanuwong, {C}. and {B}hakeecheep, {S}. and {T}raisathit, {P}. and {K}osachunhanun, {N}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}enofovir disoproxil fumarate ({TDF}) is associated with a risk of chronic kidney disease ({CKD}), especially in {A}sian populations. {D}ata from the {T}hai national health insurance system was used to assess {CKD} incidence in patients receiving antiretroviral therapy in real-world practice. {W}e analyzed data from patients who initiated one of the following first-line regimens: zidovudine + lamivudine + nevirapine ({AZT} + 3{TC} + {NVP}); zidovudine + lamivudine + efavirenz ({AZT} + 3{TC} + {EFV}); tenofovir + lamivudine + nevirapine ({TDF} + 3{TC} + {NVP}); tenofovir + lamivudine/emtricitabine + efavirenz ({TDF} + 3{TC}/{FTC} + {EFV}); and tenofovir +lamivudine +lopinavir/ritonavir ({TDF} + 3{TC} + {LPV}/r). {CKD} was defined as glomerular filtration rate <60 m{L}/min/1.73 m(2) for >3 months, or a confirmed 2010 {WHO} diagnosis ({ICD}-10 code {N}183, {N}184, or {N}185). {D}eath competing risk survival regression models were used. {A}mong 27,313 participants, with a median age of 36.8 years and median follow-up of 2.3 years, 245 patients (0.9%) were diagnosed with {CKD} (incidence 3.2 per 1000 patient-years; 95% {CI} 2.8-3.6). {C}ompared with patients receiving {AZT} + 3{TC} + {NVP}, the risk of {CKD} measured by adjusted sub-distribution hazard ratio (a{SHR}) was 6.5 (95% {CI} 3.9-11.1) in patients on {TDF} + 3{TC} + {LPV}/r, 3.8 (95% {CI} 2.3-6.0) in {TDF} + 3{TC} + {NVP}, and 1.6 (95% {CI} 1.2-2.3) in {TDF} + 3{TC}/{FTC} + {EFV}. {A}mong patients receiving {TDF}, compared with those receiving {TDF} + 3{TC}/{FTC} + {EFV}, the a{SHR} was 4.0 (95% {CI} 2.3-6.8) in {TDF} + 3{TC} + {LPV}/r and 2.3 (95% {CI} 1.4-3.6) in {TDF} + 3{TC} + {NVP}. {TDF} was associated with an increased risk of {CKD}, especially when combined with {LPV}/r or {NVP}.},
  keywords = {antiretroviral therapy ; chronic kidney disease ; {HIV} infection ; tenofovir ; disoproxil fumarate},
  booktitle = {},
  journal = {{H}ealthcare},
  volume = {10},
  numero = {8},
  pages = {1490 [13 p.]},
  year = {2022},
  DOI = {10.3390/healthcare10081490},
  URL = {https://www.documentation.ird.fr/hor/fdi:010086030},
}